Navigation Links
Karolinska Development and Kurma Biofund to Enter Strategic Partnership
Date:6/29/2010

STOCKHOLM, June 29, 2010 /PRNewswire/ -- Karolinska Development AB and Kurma Biofund have entered into a strategic partnership, with the purpose to identify co-investment opportunities in the life science area in the Nordic region and other selected parts of Europe.

The Karolinska Development and Kurma Biofund combination will increase the possibilities for early life science investments in world class science. The strategic Karolinska Development and Kurma Biofund partnership will further contribute to cross European investments.

Conny Bogentoft, CEO Karolinska Development:

"We are excited to broaden our co-investor network for early stage financing. With Kurma we also add a broader dealflow outside of Scandinavia and add a competent partner to our network."

Thierry Laugel, joint Managing Partner Kurma Biofund:

"With Karolinska Development, Kurma is proud to add such an eminent group to the very selective network of partners around Europe. We are currently looking at a number of co- investment opportunities that would clearly exemplify the complementarities and synergies between our two groups."

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that a total of 21 substances have first-in-class potential. http://www.karolinskadevelopment.com

About Kurma Biofund

Kurma Biofund is a new venture capital fund based in Paris and dedicated to innovations in Life Sciences and Healthcare. The fund has a unique positioning based on financing assets with near term realizations (3 to 5 years) for both technology transfer projects and mature projects. Kurma relies on very high quality investment opportunities generated through a network of partnerships in France and abroad with leading research institutes and a strong experienced team combining managing partners, venture partners and a strong network of scientific experts. Kurma Biofund I has closed a first round of financing of 50 million euros on the 24th November 2009. http://www.kurmabiofund.com

    For further information, please contact:

    Karolinska Development
    Conny Bogentoft: +46(0)-706-88-61-43
    conny.bogentoft@karolinskadevelopment.com

    Kurma Biofund
    Thierry Laugel : +33(0)1-58-50-91-09
    Thierruy.laugel@kurmabiofund.com



'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development and Uminova Invest Sign Co-operation Agreement
2. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
3. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
4. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
5. Karolinska Development Closes Fully Subscribed New Share Issue
6. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
7. Forza Silicon Announces High Dynamic Range CMOS Sensor Development
8. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
9. Artificial Pancreas can Prevent the Development of Hypoglycemia
10. aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
11. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
(Date:2/16/2017)... Indiana (PRWEB) , ... February ... ... of Albany Molecular Research Inc. has further extended its industry leading Biochemistry ... This service offers state-of-the-art cGMP techniques and methods for the biochemical ...
(Date:2/15/2017)... Clara, CA (PRWEB) , ... February 15, 2017 , ... ... announced that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with ... SmartScan completely automatizes all of the functions of setting up and taking the image ...
(Date:2/15/2017)... WASHINGTON , Feb. 15, 2017  NASA provider ... Services mission to the  International Space Station  no earlier ... of the launch will begin at 8:30 a.m. on ... SpaceX Dragon spacecraft will lift off on ... at NASA,s Kennedy Space Center ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
Breaking Biology News(10 mins):